Targeting cancer stem cells with an 131I-labeled anti-AC133 monoclonal antibody in human colorectal cancer xenografts

Nuclear Medicine and Biology

Volumn 42, Issue 5, 2015, Pages 505-512

  Lang, Juntao ^a,b,c   Lan, Xiaoli ^a,b   Liu, Yu ^a,b   Jin, Xueyan ^a,b   Wu, Tao ^a,b,d   Sun, Xun ^a,b   Wen, Qiong ^a,b   An, Rui ^a,b  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b HUBEI PROVINCE KEY LABORATORY OF MOLECULAR IMAGING   (China)

^c FUDAN UNIVERSITY   (China)

^d The Second People's Hospital of Wuhu   (China)

Author keywords

Cancer stem cells; Monoclonal antibody; Radioimmunoimaging; Single positron emission computed tomography (SPECT)

Indexed keywords

AC133 MONOCLONAL ANTIBODY I 131; CD133 ANTIGEN; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; GLYCOPROTEIN; LEUKOCYTE ANTIGEN; MONOCLONAL ANTIBODY; PEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; AUTORADIOGRAPHY; BINDING AFFINITY; CANCER STEM CELL; CELL SELECTION; COLORECTAL CANCER; COLORECTAL CANCER CELL LINE; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG PROTEIN BINDING; DRUG SPECIFICITY; DRUG TARGETING; DRUG UPTAKE; EX VIVO STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; IMMUNOREACTIVITY; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; LOVO CELL LINE; MAGNETIC ACTIVATED CELL SORTING; MOLECULAR STABILITY; MOUSE; NONHUMAN; NUDE MOUSE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; CELL TRANSFORMATION; COLORECTAL TUMOR; COMPUTER ASSISTED TOMOGRAPHY; IMMUNOLOGY; PATHOLOGY; RADIOGRAPHY; SCINTISCANNING; TISSUE DISTRIBUTION; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; AUTORADIOGRAPHY; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; COLORECTAL NEOPLASMS; GLYCOPROTEINS; HUMANS; MICE; MICE, NUDE; NEOPLASTIC STEM CELLS; PEPTIDES; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84926156767     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2015.01.003     Document Type: Article

References (50)

1. Wang X.L., Yuan Y., Zhang S.Z., Cai S.R., Huang Y.Q., Jiang Q., et al. Clinical and genetic characteristics of Chinese hereditary nonpolyposis colorectal cancer families. World J Gastroenterol 2006, 12:4074-4077.
2. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012, 62:10-29.
3. Edwards B.K., Ward E., Kohler B.A., Eheman C., Zauber A.G., Anderson R.N., et al. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer 2010, 116:544-573.
4. Bartlett D.L., Chu E. Can metastatic colorectal cancer be cured?. Oncology 2012, 26:266-275.
5. Neumann J., Horst D., Kriegl L., Maatz S., Engel J., Jung A., et al. A simple immunohistochemical algorithm predicts the risk of distant metastases in right-sided colon cancer. Histopathology 2012, 60:416-426.
6. Saigusa S., Tanaka K., Toiyama Y., Yokoe T., Okugawa Y., Ioue Y., et al. Correlation of CD133, OCT4, and SOX2 in rectal cancer and their association with distant recurrence after chemoradiotherapy. Ann Surg Oncol 2009, 16:3488-3498.
7. Yasuda H., Tanaka K., Saigusa S., Toiyama Y., Koike Y., Okugawa Y., et al. Elevated CD133, but not VEGF or EGFR, as a predictive marker of distant recurrence after preoperative chemoradiotherapy in rectal cancer. Oncol Rep 2009, 22:709-717.
8. Lapidot T., Sirard C., Vormoor J., Murdoch B., Hoang T., Caceres-Cortes J., et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994, 367:645-648.
9. Bonnet D., Dick J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997, 3:730-737.
10. Al-Hajj M., Wicha M.S., Benito-Hernandez A., Morrison S.J., Clarke M.F. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003, 100:3983-3988.
11. Singh S.K., Clarke I.D., Terasaki M., Bonn V.E., Hawkins C., Squire J., et al. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003, 63:5821-5828.
12. Singh S.K., Hawkins C., Clarke I.D., Squire J.A., Bayani J., Hide T., et al. Identification of human brain tumour initiating cells. Nature 2004, 432:396-401.
13. O'Brien C.A., Pollett A., Gallinger S., Dick J.E. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007, 445:106-110.
14. Collins A.T., Berry P.A., Hyde C., Stower M.J., Maitland N.J. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005, 65:10946-10951.
15. Fang D., Nguyen T.K., Leishear K., Finko R., Kulp A.N., Hotz S., et al. A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res 2005, 65:9328-9337.
16. Prince M.E., Sivanandan R., Kaczorowski A., Wolf G.T., Kaplan M.J., Dalerba P., et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci U S A 2007, 104:973-978.
17. Ma S., Chan K.W., Hu L., Lee T.K., Wo J.Y., Ng I.O., et al. Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology 2007, 132:2542-2556.
18. Yin A.H., Miraglia S., Zanjani E.D., Almeida-Porada G., Ogawa M., Leary A.G., et al. AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 1997, 90:5002-5012.
19. Ricci-Vitiani L., Lombardi D.G., Pilozzi E., Biffoni M., Todaro M., Peschle C., et al. Identification and expansion of human colon-cancer-initiating cells. Nature 2007, 445:111-115.
20. Todaro M., Alea M.P., Di Stefano A.B., Cammareri P., Vermeulen L., Iovino F., et al. Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell 2007, 1:389-402.
21. Chen Y.C., Hsu H.S., Chen Y.W., Tsai T.H., How C.K., Wang C.Y., et al. Oct-4 expression maintained cancer stem-like properties in lung cancer-derived CD133-positive cells. PLoS One 2008, 3:e2637.
22. Schatton T., Murphy G.F., Frank N.Y., Yamaura K., Waaga-Gasser A.M., Gasser M., et al. Identification of cells initiating human melanomas. Nature 2008, 451:345-349.
23. Fillmore C.M., Kuperwasser C. Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res 2008, 10:R25.
24. Eramo A., Ricci-Vitiani L., Zeuner A., Pallini R., Lotti F., Sette G., et al. Chemotherapy resistance of glioblastoma stem cells. Cell Death Differ 2006, 13:1238-1241.
25. Ma S., Lee T.K., Zheng B.J., Chan K.W., Guan X.Y. CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene 2008, 27:1749-1758.
26. Lomonaco S.L., Finniss S., Xiang C., Decarvalho A., Umansky F., Kalkanis S.N., et al. The induction of autophagy by gamma-radiation contributes to the radioresistance of glioma stem cells. Int J Cancer 2009, 125:717-722.
27. Chang C.J., Hsu C.C., Yung M.C., Chen K.Y., Tzao C., Wu W.F., et al. Enhanced radiosensitivity and radiation-induced apoptosis in glioma CD133-positive cells by knockdown of SirT1 expression. Biochem Biophys Res Commun 2009, 380:236-242.
28. Blazek E.R., Foutch J.L., Maki G. Daoy medulloblastoma cells that express CD133 are radioresistant relative to CD133- cells, and the CD133+ sector is enlarged by hypoxia. Int J Radiat Oncol Biol Phys 2007, 67:1-5.
29. Bao S., Wu Q., McLendon R.E., Hao Y., Shi Q., Hjelmeland A.B., et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006, 444:756-760.
30. Woodward W.A., Chen M.S., Behbod F., Alfaro M.P., Buchholz T.A., Rosen J.M. WNT/beta-catenin mediates radiation resistance of mouse mammary progenitor cells. Proc Natl Acad Sci U S A 2007, 104:618-623.
31. Reya T., Morrison S.J., Clarke M.F., Weissman I.L. Stem cells, cancer, and cancer stem cells. Nature 2001, 414:105-111.
32. Mizrak D., Brittan M., Alison M. CD133: molecule of the moment. J Pathol 2008, 214:3-9.
33. Miraglia S., Godfrey W., Yin A.H., Atkins K., Warnke R., Holden J.T., et al. A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning. Blood 1997, 90:5013-5021.
34. Yin S., Li J., Hu C., Chen X., Yao M., Yan M., et al. CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity. Int J Cancer 2007, 120:1444-1450.
35. Bertolini G., Roz L., Perego P., Tortoreto M., Fontanella E., Gatti L., et al. Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Proc Natl Acad Sci U S A 2009, 106:16281-16286.
36. Lin C.H., Chen W.T., Liu C.H., Tsai H.P., Wu C.C., Chai C.Y. Increased CD133 expression after preoperative chemoradiotherapy in rectal cancers other than mucin-rich tumors. Virchows Arch 2012, 460:447-453.
37. Pajonk F., Vlashi E., McBride W.H. Radiation resistance of cancer stem cells: the 4 R's of radiobiology revisited. Stem Cells 2010, 28:639-648.
38. Horst D., Scheel S.K., Liebmann S., Neumann J., Maatz S., Kirchner T., et al. The cancer stem cell marker CD133 has high prognostic impact but unknown functional relevance for the metastasis of human colon cancer. J Pathol 2009, 219:427-434.
39. Tsurumi C., Esser N., Firat E., Gaedicke S., Follo M., Behe M., et al. Non-invasive in vivo imaging of tumor-associated CD133/prominin. PLoS One 2010, 5:e15605.
40. Jin Z.H., Sogawa C., Furukawa T., Saito Y., Aung W., Fujibayashi Y., et al. Basic studies on radioimmunotargeting of CD133-positive HCT116 cancer stem cells. Mol Imaging 2012, 11:445-450.
41. Schneider M., Huber J., Hadaschik B., Siegers G.M., Fiebig H.H., Schuler J. Characterization of colon cancer cells: a functional approach characterizing CD133 as a potential stem cell marker. BMC Cancer 2012, 12:96.
42. Liu Z., Yu Z., He W., Ma S., Sun L., Wang F. In-vitro internalization and in-vivo tumor uptake of anti-EGFR monoclonal antibody LA22 in A549 lung cancer cells and animal model. Cancer Biother Radiopharm 2009, 24:15-24.
43. Vervoort L., Burvenich I., Staelens S., Dumolyn C., Waegemans E., Van Steenkiste M., et al. Preclinical evaluation of monoclonal antibody 14C5 for targeting pancreatic cancer. Cancer Biother Radiopharm 2010, 25:193-205.
44. Hu J., Zhang Y., Sun X., Li D., Li C., Qin C., et al. A novel technique for the preparation of (125)I-5-trimethylstannyl-1-(2-deoxy-2-fluoro-beta-D-arabino-furanosyl) urail and its biodistribution pattern in Kunming mice. J Huazhong Univ Sci Technolog Med Sci 2011, 31:693-695.
45. Olempska M., Eisenach P.A., Ammerpohl O., Ungefroren H., Fandrich F., Kalthoff H. Detection of tumor stem cell markers in pancreatic carcinoma cell lines. Hepatobiliary Pancreat Dis Int 2007, 6:92-97.
46. Hermann P.C., Huber S.L., Herrler T., Aicher A., Ellwart J.W., Guba M., et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007, 1:313-323.
47. Horst D., Kriegl L., Engel J., Kirchner T., Jung A. CD133 expression is an independent prognostic marker for low survival in colorectal cancer. Br J Cancer 2008, 99:1285-1289.
48. Eramo A., Lotti F., Sette G., Pilozzi E., Biffoni M., Di Virgilio A., et al. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ 2008, 15:504-514.
49. Choi D., Lee H.W., Hur K.Y., Kim J.J., Park G.S., Jang S.H., et al. Cancer stem cell markers CD133 and CD24 correlate with invasiveness and differentiation in colorectal adenocarcinoma. World J Gastroenterol 2009, 15:2258-2264.
50. Kawamoto A., Tanaka K., Saigusa S., Toiyama Y., Morimoto Y., Fujikawa H., et al. Clinical significance of radiation-induced CD133 expression in residual rectal cancer cells after chemoradiotherapy. Exp Ther Med 2012, 3:403-409.